Helen L. Bernie, DO, MPH, highlights 4 studies in sexual dysfunction being presented at the 2023 American Urological Association Annual Meeting.
In this video, Helen L. Bernie, DO, MPH, discusses 4 studies in sexual dysfunction being presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois. Bernie is director of Sexual and Reproductive Medicine at Indiana University, Indianapolis and assistant professor of urology at the Indiana University School of Medicine.
The following abstracts were previewed:
1. LBA01-12 (Ledesma et al): Platelet rich plasma for the treatment of erectile dysfunction: a prospective, randomized, double-blind, placebo controlled clinical trial
2. MP79-04 (Best et al): Stem-cell, shockwave, and platelet rich plasma therapy for the treatment of erectile dysfunction and Peyronie's disease: a survey of clinics from across the US
3. MP79-11 (Goldstein et al): A sham-controlled randomized trial of low intensity shockwave therapy for erectile dysfunction
4. PD42-02 (Barham et al): Partial component exchange of a non-infected IPP is associated with a higher complication rate
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.